SCHEMBL2011666

SCHEMBL2011666

N#Cc1ccc2c(c1)CN(CC(=O)c1ccc(OCC(=O)OCc3ccccc3)cc1)C2=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 3/20 0.46
ITGA2B P08514 3/20 0.46
POLB P06746 3/20 0.40
CYP19A1 P11511 2/20 0.40
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
AOC3 Q16853 1/20 0.38
MAOB P27338 1/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008007 0.90 ITGB3 (0.42) ITGB3ITGA2BPOLBKDM4ELMNA
SCHEMBL2012689 0.87 ALK (0.45) ITGB3ITGA2BPOLBMAPK1L3MBTL1
SCHEMBL2013867 0.87 ALDH1A1 (0.40) ITGB3ITGA2BRAB9ANPC1SMN1; SMN2
SCHEMBL2014185 0.86 ITGB3 (0.59) ITGB3ITGA2BPOLBKDM4ELMNA
SCHEMBL2007417 0.86 ITGB3 (0.50) ITGB3ITGA2BPOLBCYP19A1CYP11B1
SCHEMBL2008928 0.85 AOC3 (0.42) ITGB3ITGA2BKDM4ERAB9ANPC1
SCHEMBL2008790 0.85 ITGB3 (0.39) ITGB3ITGA2BKDM4ERAB9ANPC1
SCHEMBL2010110 0.84 ITGB3 (0.48) ITGB3ITGA2BPOLBCYP19A1CYP11B1
SCHEMBL2014017 0.83 ITGB3 (0.40) ITGB3ITGA2BCYP11B1CYP11B2KDM4E
SCHEMBL2010806 0.82 ITGB3 (0.47) ITGB3ITGA2BPOLBKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 ITGB3 169/4885ITGA2B 63/4885POLB 3689/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 ITGB3 169/4885ITGA2B 63/4885POLB 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.